TITLE

An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter

AUTHOR(S)
Geraldo Medeiros-Neto; Suemi Marui; Meyer Knobel
PUB. DATE
April 2008
SOURCE
Endocrine (1355008X);Apr2008, Vol. 33 Issue 2, p109
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract  Radioiodine (131I) treatment for nontoxic and toxic multinodular goiter (MNG) is an alternative therapeutic procedure used especially for patients with contraindication for surgery. Several studies have been conducted in recent years assessing the use of recombinant human TSH (rhTSH) in increasing 131I uptake in MNGs. This procedure also decreases the activity level of the administered 131I, changes the distribution of 131I in the thyroid, lowers the absorption dose, and dramatically reduces the volume of the goiter (50–75% of the baseline volume). A major disadvantage, however, is the induction of hypothyroidism in a relatively large number of patients. A transient increase in thyroid volume and tenderness was noted in the first week of treatment. Also a short period (2–4 weeks) of hyperthyroidism was observed in most patients with potential consequences particularly for the elderly. Still, there has been no evidence to date that the adverse effects outweigh the positive results of using rhTSH. The use of rhTSH in benign goiter disease has not yet been approved worldwide, but its positive activity in MNG is remarkable and promising.
ACCESSION #
33049332

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics